Admedus Ltd

ABN 35 088 221 078

REGISTERED OFFICE:

26 Harris Road Malaga Western Australia 6090

ASX RELEASE

ADMEDUS TO HOST SHAREHOLDER WEBINAR

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E info.au@admedus.com

www.admedus.com

  • Admedus shareholder webinar Tuesday, 28 February 2017

  • 12pm AEDT Sydney/Melbourne; 11am AEST Brisbane; 9am AWST Perth

Brisbane, Australia 16 February 2017

Admedus (ASX:AHZ) today announced that it will hold a shareholder webinar on Tuesday, 28 February 2017 to discuss the outcome of the Company's restructure to date and half yearly results.

The webinar will be presented by the Company's Chairman and Interim CEO, Mr. Wayne Paterson, and will address Admedus' business progress and performance.

The webinar will be live and shareholders are welcome to submit questions in the lead up to the webinar to: info@admedus.com

Webinar details: Date: Tuesday, 28 February 2017 Time: 12pm AEDT Sydney/Melbourne; 11am AEST Brisbane; 9am AWST Perth Please register to attend the seminar at:

https://attendee.gotowebinar.com/register/4459538179101828354

Once you have registered to attend the webinar via the link above, you will receive a confirmation email with the webcast link and dial-in details.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100

Signal Leadership Communication Inc. Mr Bob Pickard

Tel: +1 (647) 822 1000

bob.pickard@signaleadership.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC Melody A. Carey

+1 917 322 2571

mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com

Admedus Ltd. published this content on 16 February 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 15 February 2017 21:56:11 UTC.

Original documenthttp://clients2.weblink.com.au/clients/admedus/article.asp?asx=AHZ&view=6810218

Public permalinkhttp://www.publicnow.com/view/9E9379450B05F1D8449CA272791682F88EF42A1D